Department of Experimental and Clinical Biomedical, Italy
Review
Challenges in Bladder Carcinoma Treatment and Immunotherapy's Future Bladder Cancer: Current Challenges and Future Directions
Author(s): Christophe Daniel*
One of the most prevalent urological cancers with a variety of forms is bladder
carcinoma. About 90% of transitional cell cancer is caused by it (TCC). Non-muscle
invasive bladder carcinoma (NMIBC) and muscle-invasive bladder carcinoma
are the two subtypes of TCC according to histopathology (MIBC). NMIBC makes
up around 75% of bladder cancer cases with recent diagnoses. These tumours
are limited to the bladder's mucosal or submucosal area. A sizable portion of
NMIBC turns into MIBC, raising the mortality rate. Recurrence rates for bladder
cancer range from 50 to 70%, and 15% of these cases have a greater likelihood
of developing into MIBC. Nearly a quarter of bladder carcinoma patients have
the disease already spread to the bladder muscle wall when they are detected
(i.e., MIBCs). The recommended course of therapy for bladder cancer essentially
consist.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 